NEONC TECHNOLOGIES HOLDINGS, INC.
AI summary CEO and top executives invest $629,000 in open-market stock purchases following positive Phase 2a clinical data for lead asset NEO100.
- Research score
- 66
- AI adjustment
- +9
Research score, not a recommendation.
Market data
Live quote and chart from Yahoo Finance, loaded through this server. Insider purchases are marked on the chart.
–
Why this score
Research score: a weighted blend of the five factors, times the routine and offering discounts, minus the selling penalty.
Why are they buying?
AI · discretionary · catalyst credible · documentedThe insider open-market purchases closely followed the company's announcement of positive topline Phase 2a results for its lead intranasal drug candidate, NEO100, which met its primary endpoint with a statistically significant six-month progression-free survival rate.
Chief Executive Officer Amir Heshmatpour and Chief Medical Officer/CSO Thomas Chen aggressively acquired shares in the open market following the August 12, 2026 data release. Management explicitly tied these personal investments to their conviction in the strength of the clinical data and the long-term value of the company's NEO drug platform.
Filing references and sources
Stock Price & Insider Purchase History
Daily close price with open-market insider purchases plotted over time
Loading price history…
| Date | Insider | Role | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-08-14 → 2026-09-15 | Heshmatpour Amir F 9 purchases with a 63-day result · median -32.8% | CEO | 111,000 | $3.77 avg | $418.9K | |
| 2026-08-14 | Heshmatpour Amir F | 12,000 | $3.79 | $45.5K | SEC filing for Heshmatpour Amir F (opens in a new tab) | |
| 2026-08-17 | Heshmatpour Amir F | 3,000 | $4.37 | $13.1K | SEC filing for Heshmatpour Amir F (opens in a new tab) | |
| 2026-08-18 | Heshmatpour Amir F | 9,000 | $5.54 | $49.9K | SEC filing for Heshmatpour Amir F (opens in a new tab) | |
| 2026-09-11 | Heshmatpour Amir F | 37,000 | $3.67 | $135.6K | SEC filing for Heshmatpour Amir F (opens in a new tab) | |
| 2026-09-14 | Heshmatpour Amir F | 15,000 | $3.96 | $59.4K | SEC filing for Heshmatpour Amir F (opens in a new tab) | |
| 2026-09-15 | Heshmatpour Amir F | 35,000 | $3.30 | $115.4K | SEC filing for Heshmatpour Amir F (opens in a new tab) | |
| 2026-08-14 → 2026-09-14 | CHEN THOMAS C history of CHEN THOMAS C's purchases | Other C-suite | 59,814 | $4.18 avg | $250.0K | |
| 2026-08-14 | CHEN THOMAS C | 33,787 | $3.85 | $130.0K | SEC filing for CHEN THOMAS C (opens in a new tab) | |
| 2026-08-17 | CHEN THOMAS C | 2,472 | $4.04 | $10.0K | SEC filing for CHEN THOMAS C (opens in a new tab) | |
| 2026-08-18 | CHEN THOMAS C | 12,757 | $5.49 | $70.0K | SEC filing for CHEN THOMAS C (opens in a new tab) | |
| 2026-09-11 | CHEN THOMAS C | 5,556 | $3.60 | $20.0K | SEC filing for CHEN THOMAS C (opens in a new tab) | |
| 2026-09-14 | CHEN THOMAS C | 5,242 | $3.81 | $20.0K | SEC filing for CHEN THOMAS C (opens in a new tab) | |
| 2026-09-14 | GARNETT KEITHLY history of GARNETT KEITHLY's purchases | CFO | 257 | $3.89 | $1.0K | SEC filing for GARNETT KEITHLY (opens in a new tab) |
| Total | $669.9K | |||||
Other buying runs at NTHI
A run ends after a pause in the buying, so one company can have several. Returns are the stock's return minus its benchmark's (IWM for small companies, SPY otherwise), from the first open after the run became a cluster. Past results, not a forecast.
After this run became a cluster: 21 days -15.7%63 days –126 days –
| Window | Insiders | Total | Score | 21 days | 63 days | 126 days | Status |
|---|---|---|---|---|---|---|---|
| 2026-04-02 → 2026-05-01 | 4 | $476.6K | 60 | -9.5% | -37.4% | – | active |
| 2025-03-26 → 2025-05-23 | 4 | $150.3K | 45 | -44.4% | -37.6% | -18.9% | closed |